The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals, Inc. (TELO) selected Linical to support its FDA-cleared Phase 1/2 clinical trial of investigational Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer. The companies executed a Master Services Agreement and clinical trial Work Order, with clinical initiation targeted for the first quarter of 2027. The monotherapy study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity. Linical has more than two decades of oncology clinical-development experience, approximately half in early-phase studies. Telomir says Telomir-Zn is designed to regulate intracellular metal homeostasis and potentially reactivate silenced tumor-suppressor genes; preclinical research demonstrated antitumor activity in TNBC models.
Telomir Pharmaceuticals, Inc. reported a net loss of $3,417,700 for the nine months ended September 30, 2026, compared with $8,352,012 a year earlier; it reported no revenue. Cash and cash equivalents were $4,515,704 at September 30, and operating activities used $3,372,281 during the nine-month period. The FDA cleared the investigational new drug application for a Telomir-Zn trial in advanced or metastatic triple-negative breast cancer.
In October, the company sold 4,900,750 shares for approximately $5.7 million in gross proceeds at $1.13 to $1.16 per share. It plans to use net proceeds primarily for clinical development, working capital and general corporate purposes. The liquidity note says cash is insufficient to support operations for at least 12 months from issuance and raises substantial doubt about continued operations; MD&A says cash is expected to fund operations, development plans and capital expenditures into the fourth quarter of 2027. In April, Telomir acquired TELI, which held exclusive worldwide rights to develop and commercialize Telomir-Zn, and issued 34,389,710 shares to TELI’s former shareholders.
Telomir Pharmaceuticals, Inc. registered up to 5,292,810 common shares for resale by selling securityholders. The shares include 4,900,750 outstanding shares and 392,060 shares issuable upon exercise of placement agent warrants.
Telomir will not receive proceeds from selling securityholders’ resales, but may receive the warrant exercise price if warrants are exercised for cash. The completed private placement generated approximately $5.6 million in gross proceeds before placement agent fees and other offering expenses; purchasers paid $1.16 per share on October 5, 2026, and $1.13 per share on October 9, 2026.
Telomir is developing Telomir-Zn, an investigational oral small molecule. The FDA cleared its IND application for advanced or metastatic triple-negative breast cancer in April 2026, and the planned Phase 1/2 study is expected to enroll approximately 76 patients. Telomir completed its acquisition of TELI Pharmaceuticals on April 22, 2026, obtaining exclusive worldwide development and commercialization rights to Telomir-Zn.
Telomir Pharmaceuticals, Inc. (TELO) is registering 5,292,810 common shares for resale by selling securityholders: 4,900,750 outstanding shares and 392,060 shares issuable upon exercise of placement agent warrants. Holders may sell all, some or none after the registration statement becomes effective, at fixed, prevailing-market, market-related or negotiated prices. Telomir receives no resale proceeds, but may receive warrant exercise prices if warrants are exercised for cash.
The October 2026 private placement generated approximately $5.6 million in gross proceeds before placement agent fees and other offering expenses. Warrants generally require cash exercise, may be exercised cashlessly if no effective registration statement permits issuance or resale of the shares being exercised and those shares are not freely saleable under Rule 144 without volume or manner-of-sale limitations, and expire five years after issuance. The warrant ownership limit is 4.99%; holders may raise it by written notice to no more than 9.99%, with an increase effective on the 61st day after notice. Telomir is developing investigational Telomir-Zn; the FDA cleared its IND in April 2026 for advanced or metastatic TNBC, and the planned Phase 1/2 trial is expected to enroll approximately 76 patients.
Telomir Pharmaceuticals, Inc. (TELO) completed a private placement on October 5, 2026, issuing 4,843,300 common shares at $1.16 per share for approximately $5.6 million in gross proceeds. The price was a 5% discount to the applicable 10-day volume-weighted average price ending two days before closing. Existing significant shareholder John Paul DeJoria invested an additional $1.0 million. Investors received common stock only, without investor warrants, convertible securities or variable-price or reset features.
Telomir intends to use net proceeds primarily for Telomir-Zn development, including its Phase 1/2 program in advanced or metastatic triple-negative breast cancer, as well as working capital and general corporate purposes. The FDA cleared Telomir’s Investigational New Drug application, allowing the company to proceed with its first-in-human study. The placement agent’s cash fee is 9.0% of gross proceeds, approximately $455,000; Telomir also agreed to reimburse reasonable, documented accountable expenses capped at $40,000. At closing, Telomir issued the placement agent or its designees warrants for 387,464 shares, exercisable for cash at $1.16 per share and expiring five years after issuance. Telomir agreed to file a resale registration statement within 30 days of closing.
Telomir Pharmaceuticals, Inc. (TELO) reported new peer-reviewed preclinical data showing that its small molecule Telomir-Zn improved visual function and preserved retinal structure in a zebrafish model of age-related macular degeneration. After 14 days of oral dosing, Telomir-Zn enhanced several measures of visual performance and reduced retinal degeneration, with restoration of thickness across multiple retinal layers.
The study also found that Telomir-Zn reduced mitochondrial oxidative stress, increased intracellular zinc, lowered labile intracellular iron and potently inhibited multiple Fe²⁺-dependent Jumonji C histone demethylases, supporting a metal-dependent epigenetic mechanism. Relative telomeric DNA content and selected aging-associated DNA methylation patterns shifted toward a healthier profile. Despite these retinal findings, clinical development remains focused on oncology, with Telomir-Zn advancing under an FDA-cleared Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.
Telomir Pharmaceuticals, Inc. (TELO) reported the results of its 2026 Annual Meeting of Stockholders held on September 11, 2026. Stockholders owning 47,129,480 shares, or 68.53% of the 68,774,954 shares outstanding as of the July 21, 2026 record date, were represented, constituting a quorum.
All three proposals were approved, including the election of directors Erez Aminov, Matthew Whalen, Edward MacPherson and Matthew Del Giudice, M.D. For example, Aminov received 43,363,662 votes for and 93,927 withheld, with 3,671,891 broker non-votes. Stockholders also ratified Salberg & Company, P.A. as independent registered public accounting firm for 2026 with 46,998,583 votes for, and approved a possible adjournment of the meeting with 44,841,042 votes for.
Telomir Pharmaceuticals, Inc. (TELO) reported new preclinical data showing that its lead candidate Telomir-Zn inhibited cell growth in both human and canine osteosarcoma cell lines (HOS, D17, Abrams) at similar low concentrations. These in‑vitro findings support further translational work in osteosarcoma.
The company’s primary clinical effort remains a Phase 1/2 program of Telomir-Zn in advanced or metastatic triple-negative breast cancer
Telomir Pharmaceuticals, Inc. is the subject of an amended beneficial ownership report by John Paul DeJoria, acting both as trustee of the John Paul DeJoria Family Trust and in his individual capacity. He reports beneficial ownership of 3,554,871 shares of Telomir common stock. This represents 5.169% of the common stock, based on 68,774,956 shares outstanding as of August 13, 2026, as referenced from Telomir’s quarterly report. DeJoria has sole voting and dispositive power over all 3,554,871 shares and no shared voting or dispositive power.